Multimodality reperfusion therapy for acute myocardial infarction.

With the strong and direct relation between early reperfusion in acute myocardial infarction (AMI) and improved clinical outcomes, attention has focused on new means of improving rates of reperfusion and accelerating every stage of AMI evaluation and management, from the onset of symptoms of myocardial infarction to the achievement of reperfusion. Critical pathways to streamline the evaluation and management of AMI have cut minutes and even hours off in-hospital treatment times for patients with AMI; public health initiatives focus on educational efforts to shorten time to hospital arrival. The latest advance in fibrinolytic therapy is the availability of bolus fibrinolytic agents with safety and efficacy in large phase III trials comparable to accelerated intravenous infusion regimens. Faster and simpler fibrinolytic regimens may shorten door-to-needle time, reduce medication errors, and facilitate prehospital thrombolysis. Bolus fibrinolytic agents are being evaluated for use in combination with other interventions to open occluded coronary arteries, including acute percutaneous coronary intervention, the glycoprotein IIb/IIIa platelet inhibitors, or both. The goal of this "multimodality" approach to AMI management is to minimize time to reperfusion and maximize the percentage of patients who achieve complete arterial patency and myocardial perfusion without bleeding complications.

[1]  David P Miller,et al.  Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. , 2001, Journal of the American College of Cardiology.

[2]  M. Schwaiger,et al.  Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. , 2000, The New England journal of medicine.

[3]  C M Gibson,et al.  Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. , 2000, JAMA.

[4]  L. Morrison,et al.  Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. , 2000, JAMA.

[5]  C. Cannon Thrombolysis medication errors: benefits of bolus thrombolytic agents. , 2000, The American journal of cardiology.

[6]  E. Antman,et al.  Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. , 2000, Circulation.

[7]  B. Brodie,et al.  Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. , 2000, The American journal of cardiology.

[8]  R. Califf,et al.  Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial , 1999, The Lancet.

[9]  C. Cannon Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. , 1999, Journal of the American College of Cardiology.

[10]  R. Califf,et al.  Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. , 1999, The American journal of cardiology.

[11]  F. Werf Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[12]  E. Antman,et al.  Methodologic drift in the assessment of TIMI grade 3 flow and its implications with respect to the reporting of angiographic trial results. The TIMI Study Group. , 1999, American heart journal.

[13]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[14]  H. Olsson,et al.  Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. , 1999, Journal of the American College of Cardiology.

[15]  C. Cannon,et al.  Emergency department thrombolysis critical pathway reduces door‐to‐drug times in acute myocardial infarction , 1999, Clinical cardiology.

[16]  David P Miller,et al.  Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. , 1998, Circulation.

[17]  A. Kastrati,et al.  Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. , 1998, Circulation.

[18]  R. Giugliano,et al.  TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. , 1998, Circulation.

[19]  J. López-Sendón,et al.  Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. , 1998, Circulation.

[20]  J. Burchenal,et al.  Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. , 1998, Circulation.

[21]  R. Gibbons,et al.  Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction : A quantitative review , 1997 .

[22]  J. Ornato,et al.  The Physician's Role in Minimizing Prehospital Delay in Patients at High Risk for Acute Myocardial Infarction: Recommendations from the National Heart Attack Alert Program , 1997, Annals of Internal Medicine.

[23]  I. Palacios,et al.  Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. , 1997, Circulation.

[24]  T. Investigators,et al.  A comparison of reteplase with alteplase for acute myocardial infarction , 1997 .

[25]  R. Califf,et al.  Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. , 1997, Circulation.

[26]  W. Weaver,et al.  Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. , 1996, Circulation.

[27]  R. Califf,et al.  Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. , 1996, The American journal of cardiology.

[28]  C. Lambrew Emergency department triage of patients with nontraumatic chest pain , 1995 .

[29]  G. Reeder,et al.  956-115 Method of Reducing Emergency Room Time to Treatment for Acute Myocardial Infarction , 1995 .

[30]  C. Cannon,et al.  Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. , 1994, Journal of the American College of Cardiology.

[31]  E. Braunwald,et al.  GUSTO, TIMI and the case for rapid reperfusion. , 1994, Acta cardiologica.

[32]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[33]  E. Braunwald The open-artery theory is alive and well--again. , 1993, The New England journal of medicine.

[34]  R. Califf,et al.  Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. , 1993, Journal of the American College of Cardiology.

[35]  J O'Keefe,et al.  A Comparison of Immediate Angioplasty with Thrombolytic Therapy for Acute Myocardial Infarction , 1993 .

[36]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[37]  K. Fox,et al.  Effect of "fast track" admission for acute myocardial infarction on delay to thrombolysis. , 1992, BMJ.

[38]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[39]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.